Advanced Proteome Therapeutics Advances its Technological Capability

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) — Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs).

Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant factor that often requires outsourcing to other companies at considerable cost and down time. APC can now report that it has achieved a breakthrough in processing development candidates for scale up that will allow the Company to independently supply its partners with material.

The new modified protocol has enabled APC to progress collaborative programs as with Heidelberg Pharma (HDP) (Marketwired – January 08, 2018) by producing scaled-up amounts of antibody-drug conjugates with our proprietary, time-dependent, site-selective linking process. The Company can now handle the additional capacity necessary for animal testing, without resort to outsourcing and provide the requisite amounts of material at modest cost.

Allen Krantz, Chief Scientific Officer of APC, stated that “Our progress in reducing the volumes that required specialized equipment for purifying ADCs will facilitate technology transfer to our partners. The promising cytotoxicity studies that we announced in January provided the impetus for successfully scaling up our conjugative processes to accept a far larger scope of material necessary for the testing of potency and toxicity on animal subjects, which we are proud to have achieved in-house. For example, this technological advance has allowed us to efficiently produce samples for the HDP collaboration, which has now entered the animal phase of testing.”


Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells.  This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells.  The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.


Advanced Proteome Therapeutics Corporation
Bill Dickie
President and CEO
Tel: 617 358-9777

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


Primary Logo